Introduction：Basic information about CAS 331731-18-1|Adalimumab, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Adalimumab |
|---|
| CAS Number | 331731-18-1 | Molecular Weight | 434.46288 |
|---|
| Density | / | Boiling Point | / |
|---|
| Molecular Formula | C6428H9912N1694O1987S46 | Melting Point | / |
|---|
| MSDS | / | Flash Point | / |
|---|
Names
Adalimumab BiologicalActivity
| Description | Adalimumab (anti-TNF-α) is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α). |
|---|
| Related Catalog | Research Areas >>Inflammation/Immunology |
|---|
| In Vitro | Treatment of HUVECs with Adalimumab for up to 12 hours shows no adverse effect on their cell viability, even with a 10-fold higher concentration of Adalimumab (anti-TNF-α) than used in this study[2]. |
|---|
| In Vivo | The elimination half-life (t1/2) of Adalimumab (anti-TNF-α) is long (~20 days)[1]. The enriched fluorescent-labelled adalimumab (anti-TNF-α) is observed mainly in major Oil red O-positive lesions documenting good tissue penetration of the drug into the atherosclerotic plaque, without background fluorescence of the vessel wall after vehicle control injection into hypercholesterolemic Ldlr-/- mice[2]. |
|---|
| References | [1]. Ternant D, et al. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol. 2015 Feb;79(2):286-97. [2]. Oberoi R, et al. Targeting Tumor Necrosis Factor-α with Adalimumab: Effects on Endothelial Activation and Monocyte Adhesion. PLoS One. 2016 Jul 28;11(7):e0160145. |
|---|
Chemical & Physical Properties
| Molecular Formula | C6428H9912N1694O1987S46 |
|---|
| Molecular Weight | 434.46288 |
|---|
